Monteiro Patrícia Queiroz, Schaeffer Edgar, da Silva Alcides José Monteiro, Alves Carlos Roberto, Souza-Silva Franklin
Laboratório de Biologia Molecular e Doenças Endêmicas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, Rio de Janeiro 21040-900, RJ, Brazil.
Laboratório de Catálise Orgânica, Instituto de Pesquisas de Produtos Naturais Walter Mors, Universidade Federal do Rio de Janeiro, Avenida Carlos Chagas Filho 373-Bloco H, Cidade Universitária, Rio de Janeiro 21941-599, RJ, Brazil.
Int J Mol Sci. 2025 Feb 26;26(5):2025. doi: 10.3390/ijms26052025.
Leishmaniasis remains a significant public health problem in Brazil, particularly due to , which is associated with severe dermatological syndromes. The current treatments are limited by toxicity and uncertain efficacy, highlighting the need for new compounds with pharmacological potential. This study investigates chalcones as multitarget binding agents for oligopeptidase B (OPB) and cysteine proteinase B (CPB), which are critical pathogenic determinants of . The methodology involved replacing methoxy groups with aryl motifs at various positions within the chalcone structures and introducing specific functional groups at the C-4 position. This was followed by a virtual screening approach using molecular docking to assess interactions with the target proteinases. Several chalcones from the virtual library ( = 178) exhibited high binding affinities for OPB and CPB, outperforming control ligands. A total of 30 chalcones with multitarget potential were identified, with fluorinated compounds C-191 and C-135 emerging as promising inhibitors, distinguished by the best energy rankings for both enzymes. ADMET analyses confirmed the viability of these chalcones as drug candidates, with most adhering to Lipinski's rules. These data suggest that chalcones may provide new multitarget treatment options for leishmaniasis.
利什曼病在巴西仍然是一个重大的公共卫生问题,特别是由于其与严重的皮肤病综合征有关。目前的治疗方法受到毒性和疗效不确定的限制,这凸显了对具有药理潜力的新化合物的需求。本研究调查了查尔酮作为寡肽酶B(OPB)和半胱氨酸蛋白酶B(CPB)的多靶点结合剂,这两种酶是该病的关键致病决定因素。该方法包括在查尔酮结构的不同位置用芳基基序取代甲氧基,并在C-4位置引入特定的官能团。随后采用虚拟筛选方法,利用分子对接来评估与目标蛋白酶的相互作用。虚拟库(n = 178)中的几种查尔酮对OPB和CPB表现出高结合亲和力,优于对照配体。共鉴定出30种具有多靶点潜力的查尔酮,其中氟化化合物C-191和C-135成为有前景的抑制剂,在两种酶的能量排名中表现最佳。ADMET分析证实了这些查尔酮作为候选药物的可行性,大多数符合Lipinski规则。这些数据表明,查尔酮可能为利什曼病提供新的多靶点治疗选择。